Jakub Zmajkovic

Jakub Zmajkovic

Auto-generated profile, based on publicly available information

Jakub Zmajkovic

Research Institute of Molecular Pathology (IMP), Campus-Vienna-Biocenter 1

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ZGZhimin Gu
Zhimin Gu
YLYuxuan Liu
Yuxuan Liu
FCFeng Cai
Feng Cai
MPMcKenzie Patrick
McKenzie Patrick
JZJakub Zmajkovic
Jakub Zmajkovic
JXJian Xu
Jian Xu
Epigenetic gene regulation and metabolism are highly intertwined, yet little is known about whether altered epigenetics influence cellular metabolism during cancer progression. Here, we show that EZH2 and NRASG12D mutations cooperatively induce progression of myeloproliferative neoplasms to highly penetrant, transplantable, and lethal myeloid leukemias in mice. EZH1, an EZH2 homolog, is indispensable for EZH2-deficient leukemia-initiating cells and constitutes an epigenetic vulnerability. BCAT1, which catalyzes the reversible transamination of branched-chain amino acids (BCAA), is repressed by EZH2 in normal hematopoiesis and aberrantly activated in EZH2-deficient myeloid neoplasms in mice and humans. BCAT1 reactivation cooperates with NRASG12D to sustain intracellular BCAA pools, resulting in enhanced mTOR signaling in EZH2-deficient leukemia cells. Genetic and pharmacologic inhibition of BCAT1 selectively impairs EZH2-deficient leukemia-initiating cells and constitutes a metabolic vulnerability. Hence, epigenetic alterations rewire intracellular metabolism during leukemic transformation, causing epigenetic and metabolic vulnerabilities in cancer-initiating cells. Significance: EZH2 inactivation and oncogenic NRAS cooperate to induce leukemic transformation of myeloproliferative neoplasms by activating BCAT1 to enhance BCAA metabolism and mTOR signaling. We uncover a mechanism by which epigenetic alterations rewire metabolism during cancer progression, causing epigenetic and metabolic liabilities in cancer-initiating cells that may be exploited as potential therapeutics. See related commentary by Li and Melnick, p. 1158. This article is highlighted in the In This Issue feature, p. 1143

2 January 2015 in mAbs
Verified
Journal Article
Open access
HRHarald Rouha
Harald Rouha
ABAdriana Badarau
Adriana Badarau
ZVZehra C Visram
Zehra C Visram
MBMichael B Battles
Michael B Battles
BPBianka Prinz
Bianka Prinz
ENEszter Nagy
Eszter Nagy
Staphylococcus aureus is a major human pathogen associated with high mortality. The emergence of antibiotic resistance and the inability of antibiotics to counteract bacterial cytotoxins involved in the pathogenesis of S. aureus call for novel therapeutic approaches, such as passive immunization with monoclonal antibodies (mAbs). The complexity of staphylococcal pathogenesis and past failures with single mAb products represent considerable barriers for antibody-based therapeutics. Over the past few years, efforts have focused on neutralizing α-hemolysin. Recent findings suggest that the concerted actions of several cytotoxins, including the bi-component leukocidins play important roles in staphylococcal pathogenesis. Therefore, we aimed to isolate mAbs that bind to multiple cytolysins by employing high diversity human IgG1 libraries presented on the surface of yeast cells. Here we describe cross-reactive antibodies with picomolar affinity for α-hemolysin and 4 different bi-component leukocidins that share...

11 July 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TSTakafumi Shimizu
Takafumi Shimizu
LKLucia Kubovcakova
Lucia Kubovcakova
RNRonny Nienhold
Ronny Nienhold
JZJakub Zmajkovic
Jakub Zmajkovic
SMSara Christina Meyer
Sara Christina Meyer
RSRadek C. Skoda
Radek C. Skoda
Myeloproliferative neoplasm (MPN) patients frequently show co-occurrence of JAK2-V617F and mutations in epigenetic regulator genes, including EZH2. In this study, we show that JAK2-V617F and loss of Ezh2 in hematopoietic cells contribute synergistically to the development of MPN. The MPN phenotype induced by JAK2-V617F was accentuated in JAK2-V617F;Ezh2−/− mice, resulting in very high platelet and neutrophil counts, more advanced myelofibrosis, and reduced survival. These mice also displayed expansion of the stem cell and progenitor cell compartments and a shift of differentiation toward megakaryopoiesis at the expense of erythropoiesis. Single cell limiting dilution transplantation with bone marrow from JAK2-V617F;Ezh2+/− mice showed increased reconstitution and MPN disease initiation potential compared with JAK2-V617F alone. RNA sequencing in Ezh2-deficient hematopoietic stem cells (HSCs) and megakaryocytic erythroid progenitors identified highly up-regulated genes, including Lin28b and Hmga2, and chromatin immunoprecipitation (ChIP)–quantitative PCR (qPCR) analysis of their promoters revealed decreased H3K27me3 deposition. Forced expression of Hmga2 resulted in increased chimerism and platelet counts in recipients of retrovirally transduced HSCs. JAK2-V617F–expressing mice treated with an Ezh2 inhibitor showed higher platelet counts than vehicle controls. Our data support the proposed tumor suppressor function of EZH2 in patients with MPN and call for caution when considering using Ezh2 inhibitors in MPN.

8 March 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JZJakub Zmajkovic
Jakub Zmajkovic
PLPontus Lundberg
Pontus Lundberg
RNRonny Nienhold
Ronny Nienhold
MTMaria Lyngaas Torgersen
Maria Lyngaas Torgersen
ASAnders Sundan
Anders Sundan
RSRadek C. Skoda
Radek C. Skoda
Familial erythrocytosis with elevated erythropoietin levels is frequently caused by mutations in genes that regulate oxygen-dependent transcription of the gene encoding erythropoietin (EPO). We identified a mutation in EPO that cosegregated with disease with a logarithm of the odds (LOD) score of 3.3 in a family with autosomal dominant erythrocytosis. This mutation, a single-nucleotide deletion (c.32delG), introduces a frameshift in exon 2 that interrupts translation of the main EPO messenger RNA (mRNA) transcript but initiates excess production of erythropoietin from what is normally a noncoding EPO mRNA transcribed from an alternative promoter located in intron 1. (Funded by the Gebert Rüf Foundation and others.)

1 June 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
VSValéria Szijártó
Valéria Szijártó
LGLuis M. Guachalla
Luis M. Guachalla
ZVZehra C. Visram
Zehra C. Visram
KHKatharina Hartl
Katharina Hartl
CVCecília Varga
Cecília Varga
GNGábor Nagy
Gábor Nagy
TheEscherichia colisequence type 131 (ST131)-O25b:H4 clone has spread worldwide and become responsible for a significant proportion of multidrug-resistant extraintestinal infections. We generated humanized monoclonal antibodies (MAbs) that target the lipopolysaccharide O25b antigen conserved within this lineage. These MAbs bound to the surface of live bacterial cells irrespective of the capsular type expressed. In a serum bactericidal assayin vitro, MAbs induced >95% bacterial killing in the presence of human serum as the complement source. Protective efficacy at low antibody doses was observed in a murine model of bacteremia. The mode of actionin vivowas investigated by using aglycosylated derivatives of the protective MAbs. The significant binding to liveE. colicells and thein vitroandin vivoefficacy were corroborated in assays using bacteria grown in human serum to mimic relevant clinical conditions. Given the dry pipeline of novel antibiotics against multidrug-resistant Gram-negative pathogens, passive immunization with bactericidal antibodies offers a therapeutic alternative to control infections caused byE. coliST131-O25b:H4.

29 August 2014 in Cancer Microenvironment
Verified
Journal Article
Closed access
PDF file
LKLucia Kucerova
Lucia Kucerova
JZJakub Zmajkovic
Jakub Zmajkovic
LTLenka Toro
Lenka Toro
SSSvetlana Skolekova
Svetlana Skolekova
LDLucia Demkova
Lucia Demkova
MMMiroslava Matuskova
Miroslava Matuskova